Disease burden of systemic light-chain amyloidosis: a systematic literature review.

about

Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.

P2860

Q47206472-E9184263-A818-4B79-8E34-399371CB762B

P2860

Disease burden of systemic light-chain amyloidosis: a systematic literature review.

Item

http://www.wikidata.org/entity/Q38917828

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Disease burden of systemic light-chain amyloidosis: a systematic literature review.

@en

type

Item

label

Disease burden of systemic light-chain amyloidosis: a systematic literature review.

@en

prefLabel

Disease burden of systemic light-chain amyloidosis: a systematic literature review.

@en

P1476

Disease burden of systemic light-chain amyloidosis: a systematic literature review.

@en

P2093

Brian Seal

http://www.w3.org/2001/XMLSchema#string

Catherine E Cooke

http://www.w3.org/2001/XMLSchema#string

Deborah Berg

http://www.w3.org/2001/XMLSchema#string

Douglas V Faller

http://www.w3.org/2001/XMLSchema#string

Huamao Mark Lin

http://www.w3.org/2001/XMLSchema#string

Parameswaran Hari

http://www.w3.org/2001/XMLSchema#string

Richard Labotka

http://www.w3.org/2001/XMLSchema#string

Xin Gao

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study

Light-chain (AL) amyloidosis: diagnosis and treatment.

Incidence and survival in non-hereditary amyloidosis in Sweden

Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis.

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.

Economic burden of haematological adverse effects in cancer patients: a systematic review.

Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study.

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

P304

1017-1031

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/03007995.2017.1297930

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28277869

http://www.w3.org/2001/XMLSchema#string

Disease burden of systemic light-chain amyloidosis: a systematic literature review.

about

P2860

P2860

Disease burden of systemic light-chain amyloidosis: a systematic literature review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698